Mitchell E. Horwitz
Adult Stem Cell Transplant Program
Division of Cellular Therapy
Department of Medicine
Duke University Medical Center
USA
Name/email consistency: high
- Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Horwitz, M.E., Chute, J.P., Gasparetto, C., Long, G.D., McDonald, C., Morris, A., Rizzieri, D.A., Sullivan, K.M., Chao, N.J. Bone Marrow Transplant. (2012)
- Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Horwitz, M.E., Morris, A., Gasparetto, C., Sullivan, K., Long, G., Chute, J., Rizzieri, D., McPherson, J., Chao, N. Biol. Blood Marrow Transplant. (2008)
- Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. Horwitz, M.E., Spasojevic, I., Morris, A., Telen, M., Essell, J., Gasparetto, C., Sullivan, K., Long, G., Chute, J., Chao, N., Rizzieri, D. Biol. Blood Marrow Transplant. (2007)
- Chronic graft-versus-host disease. Horwitz, M.E., Sullivan, K.M. Blood Rev. (2006)
- Persistent Mycobacterium avium infection following nonmyeloablative allogeneic peripheral blood stem cell transplantation for interferon-gamma receptor-1 deficiency. Horwitz, M.E., Uzel, G., Linton, G.F., Miller, J.A., Brown, M.R., Malech, H.L., Holland, S.M. Blood (2003)
